Related Experiment Video

Updated: May 18, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Carfilzomib in multiple myeloma: gold, silver, or bronze?

Donna E Reece1

  • 1Princess Margaret Hospital, Canada.

Blood
|October 9, 2012
PubMed

Insights

Carfilzomib, a novel proteasome inhibitor, shows significant promise for treating relapsed/refractory multiple myeloma. This single-agent therapy offers meaningful disease control in patients previously unresponsive to other treatments.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • Relapsed/refractory multiple myeloma presents a significant challenge, often requiring novel therapeutic approaches.
  • Existing treatments have limitations, necessitating the exploration of new agents.

Purpose of the Study:

  • To evaluate the efficacy of carfilzomib as a single agent in patients with relapsed/refractory multiple myeloma.
  • To assess the disease control achieved with carfilzomib in a heavily pretreated patient population.

Main Methods:

  • A clinical study investigating the use of carfilzomib in patients with relapsed/refractory multiple myeloma.
  • Administration of carfilzomib as a monotherapy.

Main Results:

  • Carfilzomib demonstrated meaningful disease control in heavily pretreated patients.
  • The proteasome inhibitor showed efficacy as a single agent in this difficult-to-treat population.

Conclusions:

  • Carfilzomib represents a viable therapeutic option for relapsed/refractory multiple myeloma.
  • Single-agent carfilzomib offers a new avenue for disease management in heavily pretreated patients.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...